Briya–Luminate Collaboration Opportunities
Rapid Research Brief

Executive Summary

Key Takeaways

• Briya is scaling U.S. partnerships now — Creighton's Feb 2026 hire and the May 19 InterSystems deal show Briya is actively building its partner ecosystem.
• Luminate fills Briya's missing layer — workforce training for clinical research teams is the natural complement to a data platform that requires skilled users to extract value.
• RWD/RWE training is Luminate's proven sweet spot — they've already delivered a Real-World Data/Evidence training program for a leading pharmaceutical company (2023–present).
• Creighton's background aligns with Luminate's strengths — Watson Health and imaging AI experience means he values clinical domain expertise, not just technical platform sales.
• The meeting is well-timed — Briya is publicly signaling openness to partnerships right now; Luminate can position as the go-to training layer for Briya's pharma and CRO clients.
• Duke affiliation is a differentiator — Luminate's DCRI/Duke pedigree provides credibility that a data platform alone can't offer to risk-averse pharma clients.

Key Findings

1 Briya — Federated AI Data Platform, Not a Data Warehouse

Briya's core value proposition is connecting researchers to real-world clinical data without moving or centralizing it. "Data stays at the source, no warehouses, no duplication, no risk" [Source 1]. The AIRE platform enables natural language querying over longitudinal, heterogeneous datasets across hospital systems — purpose-built for clinical complexity. Briya emphasizes embedded compliance: "Expert determined true anonymization. Fully aligned with HIPAA, GDPR, and global standards" [Source 1]. Active deployments at Casa Sollievo della Sofferenza (Italy) and Shaare Zedek Medical Center (Israel); currently scaling into the U.S. market.

2 Luminate — Clinical Research Workforce Training, Not a Data Platform

Luminate Insights is fundamentally an education company. It delivers customizable training programs across five curriculum domains: Research Methods & Design, Data Analytics & Informatics, Research Operations & Quality, Research Ethics & Protection, and Scientific Communication & Leadership [Source 3]. Co-founded by Drs. Steven Grambow (Associate Chair of Education, Duke Biostatistics & Bioinformatics) and Hayden Bosworth (Vice Chair of Research, Duke Population Health Sciences), launched by i-Cubed / DCRI in July 2025 as a scalable capacity-building platform for pharma, CROs, medical device manufacturers, and academic institutions [Sources 3, 4].

3 The InterSystems Partnership Validates Briya's Strategy

On May 19, 2026 — the day before this brief — Briya announced a strategic partnership with InterSystems, whose IRIS platform powers over one billion health records globally. The integration allows researchers to "query complex, longitudinal datasets using simple natural language" through Briya AIRE running on InterSystems infrastructure [Source 6]. This deal demonstrates Briya's willingness to embed its platform within existing ecosystems rather than compete with them — an ecosystem partnership model that Luminate could mirror as the training layer. Lead with this in the meeting.

4 Brian Creighton Brings Enterprise Healthcare AI Sales Expertise

Creighton was appointed Executive Director of Client Strategy at Briya in February 2026 with a mandate to "drive the adoption of Briya AIRE" and "lead Briya's strategic partnerships and business expansion" [Source 5]. Prior roles: VP of Sales at Merative (cloud-native imaging solutions) and multiple leadership positions at IBM Watson Health (sales operations, complex software implementation, Health Information Exchange). His background suggests deep familiarity with the enterprise healthcare sales cycle and the importance of clinical credibility in closing deals.

5 Luminate's RWD/RWE Track Record Creates a Direct Conversation Hook

Luminate's website explicitly highlights a "Real-World Data/Real-World Evidence Training Program at a leading pharmaceutical company (2023–present)" as a marquee success story [Source 3]. Since Briya's entire platform is built on making RWD accessible for research, the logical question for Creighton is: "Once your pharma clients have Briya's data flowing, who trains their teams to design RWD studies, interpret the outputs, and avoid common methodological pitfalls?" Luminate already has a documented answer.

6 Complementary Business Models

Briya operates as a technology vendor — federated data access platform. Luminate operates as a services/education provider — custom curriculum design and delivery. These are non-overlapping, complementary business models. A partnership could create a bundled value proposition for pharma: data access (Briya) + workforce capability (Luminate) = faster, more competent real-world evidence generation.

Risks, Gaps & Uncertainty

• No public information on Briya's existing training partners — It's unknown whether Briya already has a preferred training vendor, which could affect competitive positioning.
• Luminate's partnership model and pricing not publicly documented — The specific commercial terms or partnership structures used with existing pharma clients are not available for benchmarking.
• Briya is early-stage in U.S. market — Website lists European/Israeli deployments but U.S. client logos are not publicly visible. The partnership value depends on Briya's U.S. traction.
• Different organizational cultures — Briya is an Israeli-founded tech startup; Luminate is a Duke-affiliated academic enterprise. Partnership dynamics may require bridging academic-vs-startup expectations.
• Unresolved: What does Briya specifically need from a training partner? — The meeting should surface what pain points Briya's clients experience around data literacy and whether Luminate's curriculum maps to those needs.

Recommended Next Actions

Annotated References